About this item:

506 Views | 520 Downloads

Author Notes:

Mylin A. Torres: matorre@emory.edu

Disclosure: None.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Subjects:

Research Funding:

Research reported in this publication was supported in part by the Biostatistics and Bioinformatics Shared Resource of the Winship Cancer Institute of Emory University and National Institutes of Health/National Cancer Institute under award number P30CA138292.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Surgery
  • LOCAL RECURRENCE
  • GENE-EXPRESSION
  • CONSERVING THERAPY
  • RADIATION-THERAPY
  • PROGNOSTIC VALUE
  • ADJUVANT BREAST
  • CLINICAL-TRIALS
  • MASTECTOMY
  • TAMOXIFEN
  • CHEMOTHERAPY

The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients

Tools:

Journal Title:

Annals of Surgical Oncology

Volume:

Volume 22, Number 4

Publisher:

, Pages 1088-1094

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Purpose: Although the 21-gene recurrence score (RS) assay has been validated to assess the risk of distant recurrence in hormone receptor-positive breast cancer patients, the relationship between RS and the risk of locoregional recurrence (LRR) remains unclear. The purpose of this study was to determine if RS is associated with LRR in breast cancer patients and whether this relationship varies based on the type of local treatment [mastectomy or breast-conserving therapy (BCT)]. Methods: 163 consecutive estrogen receptor-positive breast cancer patients at our institution had an RS generated from the primary breast tumor between August 2006 and October 2009. Patients were treated with lumpectomy and radiation (BCT) (n = 110) or mastectomy alone (n = 53). Patients were stratified using a pre-determined RS of 25 and then grouped according to local therapy type. Results: Median follow-up was 68.2 months. Patients who developed an LRR had stage I or IIA disease, >2 mm surgical margins, and received chemotherapy as directed by RS. While an RS > 25 did not predict for a higher rate of LRR, an RS > 24 was associated with LRR in our subjects. Among mastectomy patients, the 5-year LRR rate was 27.3 % in patients with an RS > 24 versus 10.7 % (p = 0.04) in those whose RS was ≤24. RS was not associated with LRR in patients who received BCT. Conclusions: Breast cancer patients treated with mastectomy for tumors that have an RS > 24 are at high risk of LRR and may benefit from post-mastectomy radiation.

Copyright information:

© 2014, Society of Surgical Oncology.

Export to EndNote